http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
-
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
-
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
-
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
-
MEI Pharma (MEIP) Issues Letter to Shareholders
-
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
MEI Pharma (MEIP) and Infinity Pharmaceuticals (INFI) Announce Merger Agreement
-
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
-
Bristol-Myers Squibb (BMY), Infinity Pharmaceuticals (INFI) Reports New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
-
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
-
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
-
Bristol-Myers Squibb (BMY), Infinity Pharma (INFI) Enter Advanced Solid Tumors-Focused Collaboration
-
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Advanced Solid Tumors
-
Bristol-Myers Squibb and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with IPI-549 in Advanced Solid Tumors

